The company states: "Forxiga, or dapagliflozin, has been approved in the European Union to extend the indication for heart failure with reduced ejection fraction to cover patients across the full spectrum of left ventricular ejection fraction, including HF with mildly reduced and preserved ejection fraction. The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use in December 2022 and was based on the positive results from the DELIVER Phase III trial1. Results from the prespecified pooled analysis of DELIVER and DAPA-HF Phase III trials also established Forxiga as the first HF medication to demonstrate mortality benefit across the full ejection fraction range."Reference Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AZN:
- Amgen’s Tezspire approved in U.S. for self-administration in severe asthma
- Cantor biotech/biopharma analysts hold analyst/industry conference call
- AstraZeneca continuing to work with FDA to collect data on Evusheld and variants
- FDA announces Evusheld not currently authorized for emergency use in U.S.
- AstraZeneca, Daiichi Sankyo receive EU approval for Enhertu
